REPLIMUNE GROUP, INC. Increase (Decrease) in Deferred Liabilities
REPLIMUNE GROUP, INC. (REPL) reported Increase (Decrease) in Deferred Liabilities of -$24.00 thousand for the 12-month period ending 2019-03-31, per its 10-K filed 2020-06-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2020-06-03
- REPLIMUNE GROUP, INC. increase (decrease) in deferred liabilities for the quarter ending 2019-03-31 was -$144.00K.
- REPLIMUNE GROUP, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-12-31 was $132.00K.
- REPLIMUNE GROUP, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-09-30 was -$6.00K.
- REPLIMUNE GROUP, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-06-30 was -$6.00K.
- REPLIMUNE GROUP, INC. increase (decrease) in deferred liabilities for fiscal 2019 was -$24.00K.
- REPLIMUNE GROUP, INC. increase (decrease) in deferred liabilities for fiscal 2018 was -$25.00K, a 134.25% decline from fiscal 2017.
- REPLIMUNE GROUP, INC. increase (decrease) in deferred liabilities for fiscal 2017 was $73.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2019-03-31 | -$144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | -$12.00K derived: sum of 2 quarters · filed 2020-06-03 | -$18.00K derived: sum of 3 quarters · filed 2020-06-03 | -$24.00K 10-K · filed 2020-06-03 |
| 2018-12-31 | $132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13 | $126.00K derived: sum of 2 quarters · filed 2020-02-13 | $120.00K 10-Q · filed 2020-02-13 | $113.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-09-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-12 | -$12.00K 10-Q · filed 2019-11-12 | -$19.00K derived: sum of 3 quarters · filed 2020-06-03 | -$25.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-06-30 | -$6.00K 10-Q · filed 2019-08-14 | -$13.00K derived: sum of 2 quarters · filed 2020-06-03 | -$19.00K derived: sum of 3 quarters · filed 2020-06-03 | -$25.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-03-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | -$13.00K derived: sum of 2 quarters · filed 2020-06-03 | -$19.00K derived: sum of 3 quarters · filed 2020-06-03 | -$25.00K 10-K · filed 2020-06-03 |
| 2017-12-31 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14 | -$12.00K derived: sum of 2 quarters · filed 2019-02-14 | -$18.00K 10-Q · filed 2019-02-14 | |
| 2017-09-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | -$12.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$6.00K 10-Q · filed 2018-08-30 | |||
| 2017-03-31 | $73.00K 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |